In Southeast Asia, the plant has been used for years as a substitute for opium, according to the National Center for Complementary and Integrative Health. The FDA, though, thinks differently. "Basically, what the agency is saying is that kratom behaves as an opioid and that it itself has troubling side effects," said Lyndsay Meyer, a spokeswoman f
Paris, 21 November 2017, 5.45 pm Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine Phase 3 clinical studies on-going for masitinib-gemcitabine combination in pancreatic cancer, refractory peripheral T-cell lymphoma and refractory ovarian...
Lausanne, Switzerland, November 21, 2017- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will host a Key Opinion Leader luncheon meeting on the importance of Tau as a target in Alzheimer's disease and other neurodegenerative diseases on Decem
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00 a.m. Eastern Time
Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that Dr. Gabriel Mbalaviele presented data from pre-clinical studies of Aclaris...
VANCOUVER- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European patent for AQS1301, Aequus' once-weekly transdermal patch containing aripiprazole. This is the eighth...
WASHINGTON U.S. health authorities announced plans Thursday to crack down on doctors pushing stem cell procedures that pose the gravest risks to patients amid an effort to police a burgeoning medical field that previously has received little oversight. FDA officials said they will focus their enforcement efforts on bad actors who inject st
SAN FRANCISCO- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were present
U.S. stocks rose Monday as a mix of smaller, U.S.- focused companies, technology firms and banks climbed. Merck fell after a good report from competitor Roche about a drug that competes with Merck' s cancer medication Keytruda. That's probably going to be the case throughout the week as the Thanksgiving holiday approaches and investors turn their a
AIT Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that management will hold a clinical update meeting on November 28, 2017 at 7:30 a.m. to discuss data from its NO-NTM Phase 2 clinical t
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29 th Annual Piper Jaffray Conference, taking place November 28-29, 2017 in New York, NY.. About Altimmune Altimmune is a clinical-stage immunotherapeutics co
ENGLEWOOD, Colo.- Ampio Pharmaceuticals, Inc. announced the beginning of an Open Label Extension study of Ampion in patients with severe osteoarthritis of the knee. The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial. This OLE study will address the regulatory requ
Could there be a second life for the once-popular arthritis pill Vioxx? Drugmaker Merck voluntarily pulled it off the market in 2004 because it raised the risk of heart attacks and strokes. Now a startup pharmaceutical company is working to bring Vioxx back to treat joint pain in patients with the bleeding disorder hemophilia. The Massachusetts com
WESTMINSTER, Colo.- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office's issuance of a patent on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide...
Valley Cottage, NY 11/20/2017 Improving healthcare infrastructure across several countries and regions, coupled with availability of well-developed manufacturing units, facilitates the growth of medical device businesses. In the report, titled "Auto-Injectors Market: Global Industry Analysis and Opportunity Assessment, 2016-2026," nearly...
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Initiation of two additional Phase 1 b/2 studies under collaboration with Genentech, following the first study which was initiated in July 2017. All studies are explorin
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, today announced the pricing of an underwritten public offering of 73,500,000 shares of its common stock, together with accompanying Series A common warrants to purchase an aggregate of 73,500,000 shares of common stock and Series B common...
ROCKVILLE, Md., Nov. 21, 2017/ PRNewswire/ Some of the world's largest biopharmaceutical products, among the highest revenue generators in the pharmaceutical industry, may face competition from so-called "biosimilars," according to a new report from healthcare market research firm Kalorama Information. These close copies of biodrugs are coming to
On November 21, 2017, the world leading chemical supplier BOC Sciences launched exatecan mesylate, adding to its best-selling inhibitor categories. Due to its great anticancer potential, exatecan mesylate has been broadly tested in anticancer clinical trials. This move of BOC Sciences is expected to bring much convenience for researchers who are se
PETACH TIKVA, Israel- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, Can-
Cancer Prevention Pharmaceuticals, a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29 th Annual Healthcare Conference on November 28, 7:50 -8: 10 a.m. ET at the Lotte New York Palace in New York City. In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. th
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview of the company in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 2:00pm ET at the Lotte New York Palace in New York, NY.
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of a company-sponsored, adequate and well-controlled, proof-of-concept clinical trial evaluating safety,...
-Celsion Corporation today announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound 2017 5:28. The TARDOX Study, whic
BALTIMORE, MD- Cerecor Inc. and TRx Pharmaceuticals, LLC today announced that the companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals, LLC and its franchise of commercial medications led by Poly-Vi-Flor and Tri-Vi-Flor and a merger agreement in which Cerecor will acquire Zy